|
NEW YORK (AP) -- Shares of biopharmaceutical companies mostly rose Tuesday, after a Food and Drug Administration panel voted against recommending guidelines that analysts said could pressure sales of Amgen Inc.'s anemia drugs Aranesp and Epogen and Johnson & Johnson's anemia drug Procrit. The panel met to discuss safety issues surrounding a class of drugs called erythropoiesis-stimulating agents, or ESAs. A March study showed these drugs, designed to treat anemia associated with chemotherapy treatment and in patients with kidney failure, increased the risk of heart attack, stroke and death in patients with kidney disease. The study led to stronger warnings on the drugs' labels. Aranesp was Amgen's best-selling drug in 2006, with $4.12 billion in revenue that year. Amgen shares rose $2.84, or 5.6 percent, to close at $53.88. Johnson & Johnson shares added 21 cents to $62.05. Imclone Systems Inc. rose sharply $6.97, or 18.4 percent, to close at $44.90, after the company claimed positive late-stage study results for its drug Erbitux in lung cancer. The stock earlier set a new 52-week high of $47.22. Genzyme Corp. rose $1.12 to close at $64.07, while Celgene Corp. rose $2.61, or 4 percent, to finish at 68.74. Genentech Inc. fell 85 cents to close at $78.30.
|